Description and references

Tetraphosphonate chelating agent bound to a β-emitting radionuclide; targets areas of increased bone turnover. Prepn: J. Simon et al., EP 164843; eidem, US 4898724 (1985, 1990 both to Dow); W. F. Goeckeler et al., Nucl. Med. Biol. 13, 479 (1986). Biodistribution studies: idem et al., J. Nucl. Med. 28, 495 (1987). Pharmacokinetics and clinical evaluation of pain palliation in metastatic bone cancer: M. Farhanghi et al., ibid. 33, 1451 (1992). HPLC determn in urine: W. F. Goeckeler et al., Nucl. Med. Biol. 20, 657 (1993). Chromatographic determn of radiochemical purity: H. T. Gasiglia, H. Okada, J. Radioanal. Nucl. Chem. Lett. 199, 295 (1995). Review of therapeutic potential: R. A. Holmes, Semin. Nucl. Med. 22, 41-45 (1992). Clinical trial in palliation of bone pain in hormone-refractory prostate cancer: O. Sartor et al., Urology 63, 940 (2004).

Derivative